IL319360A - Novel compounds as modulators of nlrp3 inhibition - Google Patents

Novel compounds as modulators of nlrp3 inhibition

Info

Publication number
IL319360A
IL319360A IL319360A IL31936025A IL319360A IL 319360 A IL319360 A IL 319360A IL 319360 A IL319360 A IL 319360A IL 31936025 A IL31936025 A IL 31936025A IL 319360 A IL319360 A IL 319360A
Authority
IL
Israel
Prior art keywords
modulators
novel compounds
nlrp3 inhibition
nlrp3
inhibition
Prior art date
Application number
IL319360A
Other languages
Hebrew (he)
Inventor
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Heather Jennifer Johnston
Stefanie Katharina Mesch
Jonathan Martin Shannon
Sandra Steiner
Original Assignee
Hoffmann La Roche
Lea Aurelie Bouche
Wolfgang Guba
Georg Jaeschke
Heather Jennifer Johnston
Stefanie Katharina Mesch
Jonathan Martin Shannon
Sandra Steiner
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche, Lea Aurelie Bouche, Wolfgang Guba, Georg Jaeschke, Heather Jennifer Johnston, Stefanie Katharina Mesch, Jonathan Martin Shannon, Sandra Steiner filed Critical Hoffmann La Roche
Publication of IL319360A publication Critical patent/IL319360A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
IL319360A 2022-12-07 2023-12-05 Novel compounds as modulators of nlrp3 inhibition IL319360A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22211843 2022-12-07
EP23173506 2023-05-16
PCT/EP2023/084200 WO2024121086A1 (en) 2022-12-07 2023-12-05 Novel compounds as modulators of nlrp3 inhibition

Publications (1)

Publication Number Publication Date
IL319360A true IL319360A (en) 2025-05-01

Family

ID=89073246

Family Applications (1)

Application Number Title Priority Date Filing Date
IL319360A IL319360A (en) 2022-12-07 2023-12-05 Novel compounds as modulators of nlrp3 inhibition

Country Status (15)

Country Link
US (1) US20260200901A1 (en)
EP (1) EP4630417A1 (en)
JP (1) JP2025540202A (en)
KR (1) KR20250116028A (en)
CN (1) CN120322432A (en)
AR (1) AR131278A1 (en)
AU (1) AU2023388532A1 (en)
CL (1) CL2025001654A1 (en)
CO (1) CO2025007108A2 (en)
CR (1) CR20250215A (en)
IL (1) IL319360A (en)
MX (1) MX2025005972A (en)
PE (1) PE20251845A1 (en)
TW (1) TW202440554A (en)
WO (1) WO2024121086A1 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11618751B1 (en) 2022-03-25 2023-04-04 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 derivatives
US11319319B1 (en) 2021-04-07 2022-05-03 Ventus Therapeutics U.S., Inc. Compounds for inhibiting NLRP3 and uses thereof
US12331048B2 (en) 2022-10-31 2025-06-17 Ventus Therapeutics U.S., Inc. Pyrido-[3,4-d]pyridazine amine derivatives useful as NLRP3 inhibitors
TW202545527A (en) 2024-01-16 2025-12-01 英商諾得瑟拉公司 Nlrp3 and glp-1a combination therapies

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR119731A1 (en) * 2019-05-17 2022-01-05 Novartis Ag NLRP3 INFLAMASOME INHIBITORS
LT4337652T (en) * 2021-05-12 2025-06-25 F. Hoffmann-La Roche Ag Nlrp3 inhibitors
EP4347571B1 (en) * 2021-06-04 2026-04-22 F. Hoffmann-La Roche AG Triazine derivatives and their use in the treatment of cancer.

Also Published As

Publication number Publication date
MX2025005972A (en) 2025-06-02
JP2025540202A (en) 2025-12-11
US20260200901A1 (en) 2026-07-16
CR20250215A (en) 2025-06-26
EP4630417A1 (en) 2025-10-15
AU2023388532A1 (en) 2025-02-13
TW202440554A (en) 2024-10-16
AR131278A1 (en) 2025-03-05
CN120322432A (en) 2025-07-15
WO2024121086A1 (en) 2024-06-13
PE20251845A1 (en) 2025-07-17
CO2025007108A2 (en) 2025-06-16
KR20250116028A (en) 2025-07-31
CL2025001654A1 (en) 2025-07-04

Similar Documents

Publication Publication Date Title
IL317736A (en) Compounds as inhibitors of axl
IL287472A (en) Crystal form of wee1 inhibitor compound and use thereof
EP4153591A4 (en) METHOD FOR PRODUCING WEE1 INHIBITOR COMPOUNDS
IL308071A (en) Process for the preparation of nlrp3 inhibitors
EP4271402A4 (en) Composition of bl-8040
IL314824A (en) Combination formulation of cedazuridine
GB202411655D0 (en) Application of circHIF1a
GB202307924D0 (en) Inhibitor compounds
GB202300881D0 (en) Inhibitor compounds
CA3273582A1 (en) Novel compounds as modulators of nlrp3 inhibition
IL317047A (en) Solid forms of heterocyclylamides as irak4 inhibitors
EP4262795A4 (en) Synthesis of structural analogs of largazole and associated compounds
HK40106117A (en) Tricyclic compounds as inhibitors of kras
HK40083546A (en) Tricyclic compounds as inhibitors of kras
TWI926416B (en) Inhibitor compounds for selective passivation of surfaces
HK40087466A (en) Crystal form of azetidine-substituted compound
GB202311665D0 (en) Modification of composition
GB201910665D0 (en) Novel form of compounds
HK40121003A (en) Compounds as inhibitors of axl
IL317021A (en) Synthesis of fluorosilyl compounds
IL321066A (en) Proccesses for the preparation of an nlrp3 inhibitor
GB202314050D0 (en) Novel form of bemcentinib
GB202114327D0 (en) Uses of terpenophenolic compounds
CA3280638A1 (en) Inhibitors of nlrp3
CA3266364A1 (en) Use of heteroaryloxynaphthalene compound